Nasdaq biotech merger 2026
Boundless Bio Stock Up 87% on Failed Drug and Reverse Merger Deal
Boundless Bio’s cancer drug did not work. The company is cutting three-quarters of its staff. Its stock went up 87%. Boundless Bio Hands Control to a Private Gene-Editing Startup After Its Lead Drug Fails On June 22, Boundless Bio (Nasdaq: BOLD) signed a definitive merger agreement with Serapha Bio, a privately held company developing a…
